News
IGC
0.5112
-1.69%
-0.0088
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Akanda (NASDAQ:AKAN) shares moved upwards by 69.1% to $0.16 during Wednesday's pre-market session. The company's market cap stands at $1.8 million. NanoVibronix and Predictive Oncology were among the gainers. Losers include CVRx and NRX Pharmaceuticals.
Benzinga · 3d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
IM Cannabis stock is rocketing more than 44% on plans for the Biden Administration to reclassify marijuana. Earnings reports, marijuana news, a public offering and more are moving stocks this morning. The biggest pre-market stock movers: 10 top gainers and 10 top losers.
Investorplace · 3d ago
"Schumer Says DEA Marijuana Rescheduling Decision Is 'Historic,' But He Remains 'Strongly Committed' To Passing Banking And Legalization Bills" - Marijuana Moment
Senate Majority Leader Chuck Schumer says he's committed to advancing cannabis banking and legalization legislation this session. The DEA has proposed rescheduling cannabis from Schedule I to Schedule III of the Controlled Substances Act. Schumer says the decision is a "historic step forward" but he remains committed to the legislation.
Benzinga · 4d ago
DEA Moving To Reclassify Marijuana As Less Dangerous Drug
Benzinga · 4d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Biggest pre-market stock movers on Monday are a settlement agreement, Elon Musk’s trip to China, a delisting update and more. Inno stock is rocketing more than 58% and Koninklijke Philips shares are soaring over 42% after reaching a recall settlement. Tesla shares are climbing over 19% after Elon Musk left China.
Investorplace · 5d ago
Weekly Report: what happened at IGC last week (0422-0426)?
Weekly Report · 6d ago
IGC Pharma Announces Interim Results For IGC-AD1 In Reducing Alzheimer's Agitation; Results Indicate That IGC-AD1 Clinically Reduced Agitation Compared To Placebo
Benzinga · 04/26 15:19
IGC PHARMA INC- RESULTS INDICATE THAT IGC-AD1 CLINICALLY REDUCED AGITATION COMPARED TO PLACEBO
Reuters · 04/26 15:17
Weekly Report: what happened at IGC last week (0415-0419)?
Weekly Report · 04/22 10:17
'Cannabis Seizures At Checkpoints By U.S.-Mexico Border Frustrates State-Authorized Pot Industry' - Audacy Citing AP
U.S. Border Patrol says it has the right to seize cannabis shipments at checkpoints in southern New Mexico. More than $300,000 worth of marijuana has been seized in recent months at checkpoints. New Mexico's governor says she's working to protect the state's legalized cannabis industry. Cannabis is still a "Schedule 1" drug.
Benzinga · 04/19 19:37
IGC PHARMA INC FILES FOR RESALE OF UP TO 8.8 MLN SHARES BY THE SELLING STOCKHOLDER - SEC FILING
Reuters · 04/18 10:05
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
GC Pharma Inc (IGC) released interim data from its Phase 2 clinical trial of IGC-AD1 for agitation in dementia associated with Alzheimer's. The drug shows a clinically significant reduction in agitation in Alzheimer's at week two compared to placebo. IGC Pharma's drug targets neuroinflammation and CB1 receptor dysfunction.
Benzinga · 04/16 15:47
IGC PHARMA: DEMONSTRATES CLINICAL REDUCTION, APPROACHING STATISTICAL SIGNIFICANCE, AT WEEK TWO, IN AGITATION IN DEMENTIA DUE TO ALZHEIMER'S IN STUDY
Reuters · 04/16 11:00
Who's Who In Cannabis: Latest Executive Changes You Should Know About
Decibel Cannabis Company Inc. Named Benjamin Sze as its new CEO. The Benzinga Cannabis Capital Conference gets underway in Florida this week. U.S.-based multi-state cannabis operators have surpassed the $500,000 base salary threshold in 2024. The median CEO salary in the industry is now $511,600.
Benzinga · 04/16 00:22
'Marijuana Companies Ask Federal Court To Set Oral Arguments On DOJ Claim That Cannabis 'Tourism' Justifies Prohibition Enforcement' - Marijuana Moment
Marijuana companies are asking a federal court to schedule oral arguments in a case against the federal government. The Justice Department says cannabis legalization attracts out-of-state tourism and justifies prohibition. The companies are seeking to shield their in-state activities from federal enforcement. DOJ has filed a motion to dismiss the suit.
Benzinga · 04/15 19:26
Weekly Report: what happened at IGC last week (0408-0412)?
Weekly Report · 04/15 10:12
'FDA Head Says There's 'No Reason For DEA To Delay' Rescheduling Marijuana' - Marijuana Moment
Benzinga · 04/11 18:14
Weekly Report: what happened at IGC last week (0401-0405)?
Weekly Report · 04/08 10:15
India Globalization Capital: Breakthrough in Alzheimer’s Treatment Trial
India Globalization Capital Inc (IGC) announced promising results from a Phase 2 trial of IGC-AD1. The drug shows a significant reduction in Alzheimer's-related agitation in patients. IGC could be a powerful new treatment option for managing symptoms associated with Alzheimer's disease.
TipRanks · 04/05 15:42
Weekly Report: what happened at IGC last week (0325-0329)?
Weekly Report · 04/01 10:14
More
Webull provides a variety of real-time IGC stock news. You can receive the latest news about IGC Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About IGC
IGC Pharma, Inc. is a clinical-stage pharmaceutical company. It develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome, and chronic pain. Its segments include Life Sciences and Infrastructure. It has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (THC) based formulation that is in a 146-person phase II clinical trial for agitation in dementia due to Alzheimer’s. TGR-63, a non-cannabinoid molecule, is an enzyme inhibitor shown in pre-clinical trials to reduce neurotoxicity in Alzheimer’s cell lines. It also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.